Stocks

Strategy is challenging MSCI’s proposed “nonoperating company” screen by pointing to language MSCI used in a 2022 letter to the U.S. Securities and Exchange Commission. The company argues the new methodology would force MSCI to judge whether Bitcoin should be treated as an operating asset, which it says clashes with MSCI’s stated neutrality. Strategy also says the rule would disproportionately affect MSTR, citing MSCI figures that put Strategy’s float-adjusted market capitalization at over $23.9 billion, or 86.9% of the value across six initially impacted companies.

Yum! Brands has completed the sale of Pizza Hut to private equity firm LongRange Capital, with terms not disclosed. Pizza Hut generates roughly $10 billion in global systemwide sales annually. Eduardo Luz was appointed interim CEO as the chain transitions under new ownership. Yum! Brands shares fell 0.68% on the day the completion was announced.

Yum! Brands has closed the sale of Pizza Hut to private equity firm LongRange Capital, excluding the brand’s Mainland China operations. Pizza Hut generates about $10 billion in global systemwide sales, and LongRange has appointed Eduardo Luz as interim CEO. Yum! Brands shares fell 0.68% at the time of the announcement on September 1, 2026.

Alumis said its Phase 2b LUMUS study of envudeucitinib in moderateto-severe systemic lupus erythematosus failed to meet both primary and secondary endpoints in the overall patient population. The trial enrolled 408 patients, and the primary endpoint at Week 48 did not reach statistical significance, despite stronger responses in a prespecified IFNGShigh subgroup. Following the update, Alumis shares fell about 56%, wiping out roughly $1.5B in market value.

On its fiscal 2027 first-quarter earnings call, MiniMed reported 16% organic growth. The company said the Flex product continues to expand and has received a CE mark, while Fit has filed a 510(k) application and is expected to launch in the U.S. by summer 2027. MiniMed raised its outlook and now projects about 10.5% organic revenue growth for fiscal 2027.

Pfizer shares touched a 52-week high of $29.09 on Tuesday and last traded at $28.75. The company reported Q2 2026 adjusted EPS of $0.77 on revenue of $15.03B, beating expectations of $0.68 and $14.42B. Pfizer also raised its full-year 2026 revenue outlook and said it reached a settlement covering more than 6,000 federal Depo-Provera lawsuits, removing a major legal overhang.

A committee in Switzerland’s National Council is planning to amend the banking law to raise capital requirements for systemically important banks. The proposal would take a different approach from the path previously recommended by the Federal Council. UBS shares retreated after the news emerged.

BioAffinity Technologies said it is expanding the use of its CyPath Lung test to a new application focused on recurrence monitoring for lung cancer survivors, sending the stock up more than 55% on Tuesday. Trading volume topped 17 million shares, far above the three-month average of 5.91 million. The company is studying whether the tool can help identify cancer recurrence in patients who have completed curative treatment. More than 680,000 Americans were living with a prior lung cancer diagnosis at the start of 2025.

The European Union has approved a breast cancer drug combination jointly developed by AstraZeneca and Daiichi Sankyo. The decision grants the therapy market access across Europe.